List of Excipients in API nystatin oral suspension
✉ Email this page to a colleague
Excipients in ANDA-approved (generic) drugs containing nystatin oral suspension
| Company | Ingredient | NDC | Excipient |
|---|---|---|---|
| Lannett Company Inc | nystatin oral suspension | 0527-5121 | ALCOHOL |
| Lannett Company Inc | nystatin oral suspension | 0527-5121 | ANHYDROUS CITRIC ACID |
| Lannett Company Inc | nystatin oral suspension | 0527-5121 | CARBOXYMETHYLCELLULOSE SODIUM |
| Lannett Company Inc | nystatin oral suspension | 0527-5121 | GLYCERIN |
| Lannett Company Inc | nystatin oral suspension | 0527-5121 | METHYLPARABEN |
| >Company | >Ingredient | >NDC | >Excipient |
Detailed excipient profiles for nystatin oral suspension
Excipient focus: ALCOHOL
nystatin oral suspension drug variants containing ALCOHOL
nystatin oral suspension drug variants not containing ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ANHYDROUS CITRIC ACID
nystatin oral suspension drug variants containing ANHYDROUS CITRIC ACID
nystatin oral suspension drug variants not containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CARBOXYMETHYLCELLULOSE SODIUM
nystatin oral suspension drug variants containing CARBOXYMETHYLCELLULOSE SODIUM
nystatin oral suspension drug variants not containing CARBOXYMETHYLCELLULOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CHERRY
nystatin oral suspension drug variants containing CHERRY
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | nystatin oral suspension | 80432-003 |
| >Company | >Ingredient | >NDC |
nystatin oral suspension drug variants not containing CHERRY
| Company | Ingredient | NDC |
|---|---|---|
| Lannett Company Inc | nystatin oral suspension | 0527-5121 |
| NuCare PharmaceuticalsInc | nystatin oral suspension | 68071-2644 |
| Preferred Pharmaceuticals Inc | nystatin oral suspension | 68788-7956 |
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERIN
nystatin oral suspension drug variants containing GLYCERIN
nystatin oral suspension drug variants not containing GLYCERIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: METHYLPARABEN
nystatin oral suspension drug variants containing METHYLPARABEN
nystatin oral suspension drug variants not containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLPARABEN
nystatin oral suspension drug variants containing PROPYLPARABEN
nystatin oral suspension drug variants not containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SACCHARIN SODIUM
nystatin oral suspension drug variants containing SACCHARIN SODIUM
nystatin oral suspension drug variants not containing SACCHARIN SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CITRATE
nystatin oral suspension drug variants containing SODIUM CITRATE
nystatin oral suspension drug variants not containing SODIUM CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SUCROSE
nystatin oral suspension drug variants containing SUCROSE
nystatin oral suspension drug variants not containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
nystatin oral suspension drug variants containing WATER
nystatin oral suspension drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch